Categories
Archives
Receive Email Updates
-
-
-
Certified Licensing Professionals, Inc., 2021 
Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
-
- About Me
Warren D. Woessner
Pages
Archives
Tag Archives: Warren Woessner
Myriad Argued Before The Supreme Court – Some Snippets
I confess that I’ve become addicted to this case and just finished all 63 pages of the transcript of the oral argument that took place on Monday. I won’t try to summarize it, but rather will try to review some … Continue reading
Posted in Patent Eligible Subject Matter
Tagged DNA, Myriad, Oral Arguments, Patent Law, Supreme Court, Warren Woessner
Leave a comment
Saffran v. J&J – When Defining Equals Disclaiming
A guest post from Theresa Stadheim of Schwegman Lundberg & Woessner, P.A. In Bruce N. Saffran, M.D., Ph.D., v. Johnson & Johnson and Cordis Corporation, Appeal No. 2012-1043 (Fed. Cir. April 4, 2013, decision by Lourie), the Federal Circuit reversed … Continue reading
Approaches to Claiming Diagnostic Methods using Biomarkers in the EPO
Find linked below a guest post from Dr. Stefan Danner in regards to drafting diagnostic claims in Europe. Diagnostic Claims
Posted in Patent Eligible Subject Matter
Tagged Dr. Stefan Danner, EPO, Myriad, Patent Law, Prometheus, USPTO, Warren Woessner
Leave a comment
NOVARTIS A.G. v. UOI – What is Novelty in Indian Courts?
Can everything old be made new again? Lots has been written about the Indian Supreme Court rejecting a patent application claiming a crystal modification of imatinib mesylate (Gleevec), which is used to treat CML. Novartis’ attempt to “evergreen” Gleevec with … Continue reading